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Abstract 
Methylmethaqualone is a sedative designer drug created by adding a methyl group 
to the 3-phenyl ring of methaqualone, and is at present not subject to restrictive 
regulation in many countries. To our knowledge, no case of methylmethaqualone 
abuse has been published to date in the scientific literature, and the only sources of 
information are users’ reports on Web discussion forums and data from preclinical 
animal studies. We report a case of oral methylmethaqualone abuse confirmed by 
liquid chromatography tandem mass spectrometry in a 24-year-old previously 
healthy Caucasian male. Observed symptoms and signs such as central nervous 
system depression alternating with excitation, psychomotor agitation, muscle 
hyperactivity, and tachycardia were compatible with methaqualone-induced adverse 
effects. Except for the mild tachycardia (115 beats/min), other vital signs were 
normal: blood pressure 134/89 mmHg, body temperature 36.2°C (97.16°F), 
peripheral oxygen saturation 99% while breathing room air. The ECG showed no 
prolongation of the QT interval and the QRS duration was normal. Laboratory 
analysis revealed a slight increase in creatine kinase (368 U/L) and alanine 
aminotransferase (90 U/L) serum concentrations. Blood alcohol concentration was 
0.32 g/L. Methylmethaqualone was identified in a serum sample collected on 
admission which was analyzed by a liquid chromatography tandem mass 
spectrometry toxicological screening method using turbulent flow online extraction. 
After a few days the patient ingested the same amount of substance with identical 
symptoms. Based on the chemical structure and animal data, and according to this 
case report and users’ Web reports, methylmethaqualone appears to have a similar 
acute toxicity profile to methaqualone, with marked psychomotor stimulation. 
Symptoms of acute toxicity can be expected to resolve with supportive care. 
  
Introduction 
Methylmethaqualone (MMQ), 3-(2,4-dimethylphenyl)-2-methylquinazolin-4(3H)-one, 
is a product of rational drug design, created by modifying the chemical structure of 
methaqualone by adding a methyl group to the 3-phenyl ring (Fig. 1) with the aim to 
avoid the provisions of existing drug laws but retaining psychoactive properties.1 The 
parent compound methaqualone is a highly addictive quinazolone derivative2 with 
sedative-hypnotic, anticonvulsant, and anxiolytic properties via action on the GABA-
A receptor.3 Due to its extensive history of misuse, the drug has been pulled from 
multiple markets worldwide.4,5 Other sedative quinazolone derivatives such as 
mecloqualone, cloroqualone, and etaqualone were removed from the market due to 
concerns about their potential for abuse and overdose.5 There are no reports in the 
accessible scientific literature on the human pharmacology, toxicology, and safety of 
MMQ. 
The structural identification of MMQ by mass spectrometry and proton NMR 
spectroscopy in a confiscated sample has been previously described,1 but 
established analytic methods in serum are lacking. As a consequence of structural 
similarity, the sedative-hypnotic effects of MMQ might be assumed to be similar to 
those of methaqualone, although the appearance of excitation and myoclonic states 
accompanying the hypnotic activity has been described for MMQ in animal studies.6 
Since, to our knowledge, no case of abuse of MMQ has been published in the 
literature, the only sources of information are illegal drug users’ Web discussion 
forums, in which euphoria, relaxation, memory loss, CNS depression, muscular 
spasms, and seizures are mentioned in a dose-dependent manner.7 A search of the 
US-based National Poison Database System (NPDS) between 2009-2010 retrieved 
no mentions of methylmethaqualone/MMQ.  
MMQ is generally used in doses of 50 to 200 mg; 300 mg are reported to induce 
muscle twitching, muscular spasms, and prolonged sedation.7,8 Effects are described 
to begin after 20 to 30 minutes, and to persist for 4 to 6 hours.7,8 MMQ is usually 
ingested, although sublingual application and smoking of lower doses has rarely 
been reported.7,8 We present a case of MMQ abuse confirmed by the identification of 
the substance in serum by liquid chromatography tandem mass spectrometry.  
 
Case report 
A 24-year-old previously healthy Caucasian male was admitted to the emergency 
department (ED) of our hospital following the acute onset of severe psychomotor 
agitation. One hour before admission, the patient was found at home by his parents 
in a somnolent state which suddenly switched to severe psychomotor agitation with 
generalized clonic muscle contractions and urinary incontinence. Paramedics found 
the patient extremely agitated and confused, and administered 10 mg midazolam 
intravenously with subsequent improvement in agitation. The patient admitted to 
having ingested up to two 500 mg MMQ tablets (obtained from a friend who had 
bought them from a dealer) with wine that evening (approximately 2 - 3 hours before 
admission to the ED) for recreational purposes. 
On arrival to the ED, the patient was intermittently confused but his agitation had 
resolved. Except for a mild tachycardia (115 beats/min), vital signs were normal 
(blood pressure 134/89 mmHg, body temperature 36.2°C (97.16°F), peripheral 
oxygen saturation 99% while breathing room air). The neurological examination 
revealed a mild generalized resting tremor of upper and lower limbs. The pupils were 
mydriatic (moderate dilatation of approximately 7 mm) with normal reaction to light. 
No nystagmus was observed. The rest of the neurological examination and the 
general physical examination were unremarkable. 
The ECG was normal, except for mild sinus tachycardia; there was no prolongation 
of the QT interval and the QRS duration was normal (89 ms). Laboratory analysis 
revealed a slight increase in creatine kinase (368 U/L; reference range 0 - 200 U/L) 
and alanine aminotransferase (90 U/L; reference range < 41 U/L) serum 
concentrations. Blood alcohol concentration was 0.32 g/L (the legal alcohol limit for 
drivers in the UK is 0.8 g/L). Other parameters, including serum electrolytes, 
creatinine, complete blood count, other liver function tests, and thyroid stimulating 
hormone level were within normal limits. Arterial blood gas analysis (room air) 
showed pH 7.418, pO2 11.5 kPa (86 mmHg), pCO2 5.07 kPa (38 mmHg), SatO2 
97%, bicarbonate 24.1 mmol/L, and lactate concentration 2.0 mmol/L. ELISA urine 
toxicology screen was negative for benzodiazepines, cocaine, amphetamine, tetra-
hydro-cannabinol, opioids, barbiturates, methadone, TCAs, MDMA, and 
methamphetamines.  
A serum sample collected on admission was analyzed by a liquid chromatography 
tandem mass spectrometry toxicological screening method using turbulent flow 
online extraction.9,10 MMQ was identified by comparing the MS2 and MS3 spectra 
with the respective spectra of methaqualone, whose library spectra produced from a 
pure reference compound were available in the spectral library of the Institute for 
Clinical Chemistry, University Hospital Zurich.9 Because of the additional methyl 
group, the mass-to-charge ratio of the protonated molecule [M+H]+ of MMQ was 
increased by 14 amu ([M+H]+ of methaqualone: m/z 251, [M+H]+ of MMQ: m/z 265). 
Depending on which part of the molecule the fragments of MMQ were derived from, 
they either had the same mass-to-charge ratio as the respective fragments of 
methaqualone, or, if the fragment contained the moiety with the additional methyl 
group which MMQ has compared with methaqualone, their mass-to-charge ratio was 
increased by 14 amu (Fig. 2). 
Using the same liquid chromatography tandem mass spectrometry screening 
method, a search for a wide variety of medications and drugs of abuse (more than 
900 substances) was performed (general unknown screening). Besides midazolam 
(which was administered by prehospital emergency services), no other substances 
were identified. 
The patient was admitted to the medical ward for observation. The subsequent 
clinical course was uneventful and he was therefore discharged home on the 
following day. 
Ten days later the patient presented identical symptoms and signs after a repeated 
ingestion of the same amount of MMQ tablets. The response to 15 mg midazolam 
administered intramuscularly by paramedics was favourable. ELISA urine toxicology 
screen was negative. Blood alcohol concentration was < 0.05 g/L and creatine 
kinase 225 U/L. After initial evaluation in the ED and following 2 hours uneventful 
observation, the patient was discharged home with the recommendation to consult a 
psychiatrist.  
 
Discussion 
Recent years have been characterised by a dramatic increase in the production and 
sale, mainly through the Internet, of designer drugs with primarily stimulant, 
entactogenic, and hallucinogenic properties,11 although designer sedatives such as 
MMQ and mebroqualone are also available on the market.1,8 Designer drugs can 
have highly similar chemical structures to existing illegal drugs of abuse, in order to 
elude existing regulations but to retain psychoactive properties of the parent 
compound.12 Actually, MMQ is the methylated analogue, but not a metabolite,13 of 
methaqualone, which is a quinazoline compound related functionally and structurally 
to glutethimide and the barbiturates.14 The numerous cases of abuse of 
methaqualone reported soon after its introduction to the market, indicated a marked 
addictive potential of this substance which was also causing a severe withdrawal 
syndrome similar to delirium tremens characteristic of the sedative-hypnotic type of 
dependence.15 Methaqualone was therefore withdrawn from the market in many 
developed countries in the early 1980s, and was listed in the UK as a class B drug 
under the Misuse of Drugs Act 1971 and classified as a Schedule I drug in the US in 
1984. In contrast, to our knowledge, MMQ is at present not subject to restrictive 
regulations in many countries, especially those having no general analogue act or 
equivalent legislation.  
Methaqualone overdose usually causes ataxia, lethargy, and CNS depression, 
although limb hyperreflexia, myoclonia, seizures, coma and other non-neurological 
symptoms such as respiratory and cardiac failure have been described after severe 
poisoning.14,16 Psychomotor agitation was observed in a life-threatening 
intoxication,17 and, at lower doses, recreational users have reported a euphoriant 
effect.18 
MMQ users describe similar effects to those of methaqualone, and the symptoms 
and signs observed in our patient (CNS depression followed by psychomotor 
agitation, muscle hyperactivity, and tachycardia) are compatible with methaqualone-
induced adverse effects. Furthermore, muscle hyperactivity presenting as muscle 
twitching or muscular spasms described as similar to GHB-induced seizures, is 
mentioned as undesirable effect in anecdotal reports of MMQ users,7 and was also 
observed in our patient. Moreover, animal studies have shown that MMQ can 
produce excitation and myoclonic states at doses only slightly above the effective 
sedative dose.6 The initial neurological presentation of our patient is also compatible 
with an epileptic seizure, which has been reported after abuse of both MMQ7 and 
methaqualone.17 
A common dose of methaqualone for recreational use is reported to be 300 mg.19 
However, tolerance develops rapidly and some users may take up to 1000 - 2000 
mg per day.20 Users’ reports discuss a higher potency of MMQ compared to 
methaqualone, and recommend doses of 50 - 200 mg of the former for recreational 
use.7,8 However, in an animal study, mice required higher doses of MMQ compared 
to methaqualone to achieve a hypnotic effect.6 In our case, 500 - 1000 mg of 
substance were ingested in the form of tablets and not as pure powder, therefore the 
effective ingested dose of MMQ might have been overestimated due to the possible 
presence of adulterants (e.g. starch, mannitol, inositol). 
As a methaqualone-derivative, MMQ is likely addictive and therefore has potential for 
abuse but, at present, is not subject to restrictive regulations in many countries. Thus 
it seems plausible that the illicit use of this substance might increase internationally. 
For this reason, further studies are needed to determine the pharmacological and 
toxicological properties of MMQ, and to analyze patterns of acute toxicity in humans 
and its possible long-term effects, including dependency and withdrawal. 
 
In conclusion, MMQ appears to have a similar acute toxicity profile to methaqualone, 
with marked psychomotor stimulation. Symptoms of acute toxicity can be expected 
to resolve within hours with supportive care.  
  
Patient’s consent 
A document showing the patient’s written consent to this publication is available on 
demand. 
 
Acknowledgements 
We thank Dr. Hugo Kupferschmidt, Swiss Toxicological Information Centre, for 
valuable discussions during the preparation of the manuscript, and Ms. Rose-Marie 
Hauser-Panagl for secretarial assistance. 
 
Declaration of interest 
None of the authors has conflicts of interest concerning commercial or financial 
involvements. No author is affiliated with an organization whose financial interests 
may be affected by material in the manuscript. 
 
References 
1. Angelos SA, Lankin DC, Meyers JA, Raney JK. The structural identification of a 
methyl analog of methaqualone via 2-dimensional NMR techniques. J Forensic Sci. 
1993; 38:455-465. 
2. Gillman MA, Harker N, Lichtigfeld FJ. Combined cannabis/methaqualone 
withdrawal treated with psychotropic analgesic nitrous oxide. Int J Neurosci. 2006; 
116:859-869. 
3. Naik SR, Naik PR, Sheth UK. Involvement of gamma-amino butyric acid (GABA) 
in the anticonvulsant action of methaqualone. Psychopharmacology (Berl). 1978; 
57:103-107. 
4. van Zyl EF. A survey of reported synthesis of methaqualone and some positional 
and structural isomers. Forensic Sci Int. 2001; 122:142-149. 
5. Watanabe K. Screening colour test and specific colour test for the detection of 
non-barbiturate sedatives and hypnotics methaqualone and mecloqualone. United 
nations international drug control programme. 1996; Scitec/13. 
6. Boltze KH, Dell HD, Lehwald H, Lorenz D, Rueberg-Schweer M. Substituted 4-
quinazolinone derivatives as hypnotics and anticonvulsants. Arzneimittelforschung 
1963; 13:688-701. 
7. http://www.drugs-forum.com/forum/showthread.php?t=55413#ixzz1lKVcHbUA; 
last accessed on Aug 27, 2012. 
8. http://eve-rave.ch/Forum/viewtopic.php?f=96&t=25618; last accessed on Aug 27, 
2012. 
9. Mueller DM, Duretz B, Espourteille FA, Rentsch KM. Development of a fully 
automated toxicological LC-MS(n) screening system in urine using online extraction 
with turbulent flow chromatography. Anal Bioanal Chem. 2011; 400:89-100. 
10. Mueller DM, Rentsch KM. Online extraction toxicological MS(n) screening 
system for serum and heparinized plasma and comparison of screening results 
between plasma and urine in the context of clinical data. J Chromatogr B Analyt 
Technol Biomed Life Sci. 2012; 1;883-884: 189-197. Epub 2011 Aug 24. 
11. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol 
(Phila). 2011; 49:705-719. 
12. Gibbons S, Zloh M. An analysis of the 'legal high' mephedrone. Bioorg Med 
Chem Lett. 2010; 20:4135-4139. 
13. Prost F, Thormann W. Enantiomeric analysis of the five major monohydroxylated 
metabolites of methaqualone in human urine by chiral capillary electrophoresis. 
Electrophoresis. 2001; 22:3270-3280. 
14. Brown SS, Goenechea S. Methaqualone: metabolic, kinetic, and clinical 
pharmacologic observations. Clin Pharmacol Ther. 1973;14:314-324. 
15. Madden JS. A guide to alcohol and drug dependence. Bristol: John Wright & 
Sons; 1979. 
16. Kurz RW, Hainz R, Gremmel F, Grisold W, Hruby K, Dellert P, Vycudilik W. 
Dangerous intoxication from extreme serum concentrations of methaqualone 
metabolites. Detection and quantification of biosynthesis with gas chromatography-
mass spectrometry. Anaesthesist. 1995; 44:863-868. 
17. Abboud RT, Freedman MT, Rogers RM, Daniele RP. Methaqualone poisoning 
with muscular hyperactivity necessitating the use of curare. Chest. 1974; 65:204-
205. 
18. Ionescu-Pioggia M, Bird M, Orzack MH, Benes F, Beake B, Cole JO. 
Methaqualone. Int Clin Psychopharmacol. 1988; 3:97-109. 
19. Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th ed. Foster City, 
CA: Biomedical Publications; 2002: 657-659. 
20. Verma R, Tiwari N. Phenytoin intoxication induced by Mandrax (methaqualone). 
Epilepsy Res. 2012; 98:281-282. 
 
